6533b871fe1ef96bd12d1971

RESEARCH PRODUCT

Improved inter-observer agreement of an expert review panel in an oncology treatment trial--Insights from a structured interventional process.

Susanne Martina EschmannCornelia PuskasAnca-ligia GrosuFriederike RühlWerner VachUrsula NestleGabriele HollV. Duncker-rohrMatthias MiedererMichail PlotkinAnja LeifertM. ToschMarkus EsslerMichael MixJochem KönigTanja Schimek-jaschHans Christian Rischke

subject

Cancer Researchmedicine.medical_specialtyLung NeoplasmsContext (language use)Sensitivity and SpecificityDouble-Blind MethodFluorodeoxyglucose F18Carcinoma Non-Small-Cell LungOutcome Assessment Health CaremedicineData monitoring committeeHumansMedical physicsObserver VariationPET-CTmedicine.diagnostic_testbusiness.industryReproducibility of ResultsChemoradiotherapyClinical trialOncologyPositron emission tomographyPositron-Emission TomographyRadiologybusinessTomography X-Ray ComputedQuality assuranceKappaChemoradiotherapy

description

Abstract Purpose Oncologic imaging is a key for successful cancer treatment. While the quality assurance (QA) of image acquisition protocols has already been focussed, QA of reading and reporting offers still room for improvement. The latter was addressed in the context of a prospective multicentre trial on fluoro-deoxyglucose (FDG)–positron-emission tomography (PET)/CT-based chemoradiotherapy for locally advanced non-small cell lung cancer (NSCLC). Material and methods An expert panel was prospectively installed performing blinded reviews of mediastinal NSCLC involvement in FDG–PET/CT. Due to a high initial reporting inter-observer disagreement, the independent data monitoring committee (IDMC) triggered an interventional harmonisation process, which overall involved 11 experts uttering 6855 blinded diagnostic statements. After assessing the baseline inter-observer agreement (IOA) of a blinded re-review (phase 1), a discussion process led to improved reading criteria (phase 2). Those underwent a validation study (phase 3) and were then implemented into the study routine. After 2 months (phase 4) and 1 year (phase 5), the IOA was reassessed. Results The initial overall IOA was moderate (kappa 0.52 CT; 0.53 PET). After improvement of reading criteria, the kappa values improved substantially (kappa 0.61 CT; 0.66 PET), which was retained until the late reassessment (kappa 0.71 CT; 0.67 PET). Subjective uncertainty was highly predictive for low IOA. Conclusion The IOA of an expert panel was significantly improved by a structured interventional harmonisation process which could be a model for future clinical trials. Furthermore, the low IOA in reporting nodal involvement in NSCLC may bear consequences for individual patient care.

10.1016/j.ejca.2015.07.036https://pubmed.ncbi.nlm.nih.gov/26277100